| EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Colorectal
cancer
HIGH-DOSE BEVACIZUMAB IMPROVES SURVIVAL WHEN COMBINED WITH
FOLFOX4 IN PREVIOUSLY TREATED ADVANCED COLORECTAL CANCER:
RESULTS FROM THE EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG)
STUDY E3200. (ABSTRACT 2)
Pancreatic
cancer
ERLOTINIB PLUS GEMCITABINE COMPARED TO GEMCITABINE ALONE IN
PATIENTS WITH ADVANCED PANCREATIC CANCER. A PHASE III TRIAL
OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS
GROUP [NCIC-CTG]. (ABSTRACT 1)
Breast
cancer
E2100: A RANDOMIZED PHASE III TRIAL OF PACLITAXEL VERSUS PACLITAXEL
PLUS BEVACIZUMAB AS FIRST-LINE THERAPY FOR LOCALLY RECURRENT
OR METASTATIC BREAST CANCER.
E2197: PHASE III AT (DOXORUBUCIN/DOCETAXEL)
VS. AC (DOXORUBICIN/ CYCLOPHOSPHAMIDE) IN THE ADJUVANT TREATMENT
OF NODE POSITIVE AND HIGH RISK NODE NEGATIVE BREAST CANCER.
(ABSTRACT 512)
| 
